Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
NORTH CHICAGO, Ill., Dec. 14, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2021 Category: Drugs & Pharmacology Source Type: news
Malignancy Risk in Patients With Secukinumab-treated Psoriasis Malignancy Risk in Patients With Secukinumab-treated Psoriasis
Does treatment with secukinumab increase the risk of malignancy in patients being treated for psoriasis, psoriatic arthritis, or ankylosing spondylitis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Patient Pathways to Diagnosis of Psoriatic Arthritis Patient Pathways to Diagnosis of Psoriatic Arthritis
Gain a better understanding of the symptoms that may precede a psoriatic arthritis diagnosis and patients ' experiences in obtaining the diagnosis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Guselkumab Deemed Effective for PsA Previously Treated With TNFi Guselkumab Deemed Effective for PsA Previously Treated With TNFi
COSMOS trial results in patients with psoriatic arthritis fit with the expectation that"people who ' ve previously failed a TNF inhibitor might be a little less likely to respond to guselkumab."Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 2, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
Psoriatic Arthritis Highlights From ACR 2021 Psoriatic Arthritis Highlights From ACR 2021
Dr Christopher Ritchlin discusses key reports on psoriatic arthritis from ACR 2021, including results of a brepocitinib efficacy study and data on risk factors for progression and patient concerns.Medscape (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 24, 2021 Category: Orthopaedics Tags: Rheumatology ReCAP Source Type: news
Psoriatic Arthritis: Looking for the Unexpected Psoriatic Arthritis: Looking for the Unexpected
Jennifer Kwan-Morley, MD, discusses advances in the treatment of psoriatic arthritis that she has witnessed in her career.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 23, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news
Psoriatic Arthritis: The Importance of Multidisciplinary Teams and Mentors Psoriatic Arthritis: The Importance of Multidisciplinary Teams and Mentors
Jennifer Kwan-Morley, MD, reflects on the mentors who helped shape her approach to psoriatic arthritis.Medscape (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 22, 2021 Category: Orthopaedics Tags: Rheumatology MDAngle Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Psoriatic Arthritis Management: From Intramuscular Gold to Biologics Psoriatic Arthritis Management: From Intramuscular Gold to Biologics
Phillip J. Mease, MD, reflects on the development of therapeutics for psoriatic arthritis, from intramuscular gold and oral methotrexate in former decades, to the recent use of biologics.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2021 Category: Consumer Health News Tags: Rheumatology MDAngle Source Type: news
How the COVID-19 Pandemic Has Affected Psoriatic Arthritis Care How the COVID-19 Pandemic Has Affected Psoriatic Arthritis Care
Saakshi Khattri, MD, discussing navigating the first days of the COVID-19 pandemic with her psoriatic arthritis patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news
Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis
At the 24-week assessment, participants receiving risankizumab showed greater improvement in primary and secondary endpoints than did placebo with no new safety signals.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
Three Signs Point to a Diagnosis of Psoriatic Arthritis Three Signs Point to a Diagnosis of Psoriatic Arthritis
Dactylitis, an inflamed sausage-like finger or toe, is a classic finding of psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 7, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
A Look Ahead: The Goal of Precision Medicine in Psoriatic Arthritis A Look Ahead: The Goal of Precision Medicine in Psoriatic Arthritis
How Saakshi Khattri, MD, envisions a future of precision medicine in psoriatic arthritis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 4, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news
New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [ACR] 20/50/70)a a...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
